Why this is on people's radar
5-Amino-1MQ (5-amino-1-methylquinolinium) emerged from research on NNMT, an enzyme that's chronically elevated in obese adipose tissue. NNMT consumes nicotinamide and SAM (S-adenosylmethionine) to produce 1-methylnicotinamide, depleting cellular methyl pools and reducing nicotinamide availability for NAD+ synthesis. The hypothesis was that inhibiting NNMT in obesity could rebalance the cellular methylation and energy economy, reducing fat storage.
Animal studies from Jay Barth's University of Texas Southwestern lab and others have reported impressive results: mice on high-fat diets given 5-Amino-1MQ lost fat mass without changes in food intake, with shifts in adipocyte metabolism consistent with the proposed mechanism. The findings sparked early-stage commercial interest, and 5-Amino-1MQ moved from academic research into research-peptide and biohacker channels much faster than the human evidence base supported.
The honest framing: the underlying biology is interesting, the mouse data is striking, the human translation has not happened. People taking 5-Amino-1MQ in research-peptide channels for fat loss are participating in self-experimentation with an early-stage research compound.
What people are usually trying to do with it
People exploring 5-Amino-1MQ are usually focused on:
- Fat loss without dietary changes
- An adjunct to existing weight-loss protocols
- Following the longevity / NAD+ / methylation research at a more experimental edge
- An alternative or complement to GLP-1 medications
What the science actually shows
Plain-English summary:
NNMT biology
NNMT is elevated in obese adipose tissue and contributes to the metabolic dysfunction characteristic of obesity. Inhibiting NNMT is a real, biologically interesting target.
Mouse fat-loss data
Animal studies have reported significant fat-mass reductions in obese mice given 5-Amino-1MQ, even without dietary changes. The findings are real but preclinical.
Human evidence
Essentially absent. No registered Phase 1 trials of meaningful scale as of 2026.
What hasn't been demonstrated
Anything in humans. Human safety, efficacy, dosing, pharmacokinetics, none of it is characterized at the level needed to support clinical use.
The honest read
What's solid:
The NNMT-inhibition hypothesis is biologically interesting and the animal data is striking. The compound represents real preclinical research.
What's still completely unknown:
Anything about human use. No human clinical trials. No human safety data. No human dose-response characterization. Long-term effects of NNMT inhibition in humans are unknown.
What's hyped beyond the evidence:
Marketing of 5-Amino-1MQ as a fat-loss product. The compound is preclinical research that's been pulled into research-peptide channels far ahead of any human evidence. People comparing it to GLP-1 medications, which have been through extensive clinical development with massive trial programs, are comparing a research tool to an FDA-approved drug class with established safety and efficacy.
Things to know if you're looking into it
- Preclinical only: the most important fact about this compound. No human trials.
- Not technically a peptide: small-molecule NNMT inhibitor, included on this site because of overlapping fat-loss conversation.
- Sourcing concerns: compounds at this preclinical stage available in research-peptide channels have no manufacturing oversight or quality control comparable to clinical-stage drugs.
- Regulatory status: not FDA-approved. Not on the FDA Category 2 list.
- For real fat loss: evidence-based options (lifestyle, GLP-1 medications when indicated, established weight-loss programs) have substantially more rigorous evidence than 5-Amino-1MQ.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Will 5-Amino-1MQ help me lose fat?
Mouse data is striking. Human data essentially doesn't exist. Anyone using it now is participating in self-experimentation with an early-stage research compound.
Is it FDA-approved?
No. Preclinical research only. Not in registered Phase 1 trials of meaningful scale.
How does it compare to GLP-1 medications like semaglutide?
Different category entirely. GLP-1s are FDA-approved drugs with extensive Phase 3 trial programs and established safety/efficacy. 5-Amino-1MQ is a preclinical research compound.
Is it safe?
No human safety data exists. Long-term effects of NNMT inhibition in humans are uncharacterized.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved. Preclinical research stage. No meaningful human clinical trials registered. Not on the FDA Category 2 list. Status updates land here when they happen.
Want to go deeper?
Mechanism, the NNMT context, and references.
Background
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor identified through structure-based drug-design work targeting the enzyme.
Mechanism of action
NNMT methylates nicotinamide using SAM as the methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. Elevated NNMT in obese adipose tissue depletes cellular SAM and nicotinamide pools, contributing to metabolic dysfunction. 5-Amino-1MQ inhibits NNMT, theoretically restoring those pools and reducing fat-cell hypertrophy.
References
- Kraus D, Yang Q, Kong D, et al. (2014). "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature, 508(7495), 258–262. PubMed
- Neelakantan H, Vance V, Wang HY, et al. (2018). "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochem Pharmacol, 147, 141–152. PubMed